Ovarian cancer remains the deadliest gynecologic malignancy. Current treatment has low efficacy in the long term, leading to low 5-year survival rates of 20-40%. Treatment-free periods between cycles of chemotherapy are accepted in standard treatment. These periods lead to accelerated tumor cell proliferation, angiogenesis and drug resistance development. Studies
presented herein show advantages of continuous carboplatin dosing schedule over conventional intermittent regimen, both administered intraperitoneally. Continuous carboplatin therapy blocked acceleration of cell proliferation observed during treatment-free period of intermittent therapy. Moreover, continuous carboplatin led to 57% inhibition of SKOV3 tumors grown intraperitoneally in SCID mice, a significant advantage over the 33% tumor suppression observed with intermittent carboplatin. Immunohistochemical analysis revealed continuous carboplatin led to greater tumor cell death while suppressing tumor cell proliferation and angiogenesis when compared to intermittent administration. These results show that the
suppression of tumor growth with carboplatin can be enhanced by the elimination of treatment free periods.
| Identifer | oai:union.ndltd.org:TORONTO/oai:tspace.library.utoronto.ca:1807/33787 |
| Date | 04 December 2012 |
| Creators | Zhidkov, Nickholas |
| Contributors | Piquette-Miller, Micheline |
| Source Sets | University of Toronto |
| Language | en_ca |
| Detected Language | English |
| Type | Thesis |
Page generated in 0.0017 seconds